TY - JOUR
T1 - The EHA research roadmap
T2 - Blood coagulation and hemostatic disorders
AU - Eichinger, Sabine
AU - Morange, Pierre E.
AU - Cattaneo, Marco
AU - Fretigny, Mathilde
AU - Rauch, Antoine
AU - van Hylckama Vlieg, Astrid
AU - Trégouët, David-Alexandre
AU - Ruf, Wolfram
AU - Levi, Marcel
AU - Páramo, José A.
AU - van der Poll, Tom
AU - Kyrle, Paul A.
AU - Garagiola, Isabella
AU - Peyvandi, Flora
N1 - Funding Information: SE received royalties of payments from Bayer, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, CSL-Behring, Takeda, and Pfizer. MC is an Advisory board member in Astra Zeneca. AR received research grant from CSL Behring, LFB, and Roche/Chugai; a clinical trials investigator for Biomarin, Bioveratin, CSL Behring, Shire/Takeda, and Sobi; and an Advisory board member for LFB, Octapharma, Roche, and Sobi. WR is a consultant for ARCA Biopharma and ICONIC Therapeutics; received research grants from ICONIC andARCA Biopharma; and ownership interest for MeruVasimmune. ML is in Occasional Advisory Boards of Lilly, Novo Nordisk, and Asahi Kasei. JAP received royalties of payments from Stago, Octapharma, and CSL Behring. FP participated in educational meetings and advisory boards for Sanofi, Roche, Sobi, and Takeda. All the other authors have no conflicts of interest to disclose. Publisher Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
PY - 2021
Y1 - 2021
N2 - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.
AB - In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally funded future for European hematology research. The 11 EHA Research Roadmap sections include Normal Hematopoiesis; Malignant Lymphoid Diseases; Malignant Myeloid Diseases; Anemias and Related Diseases; Platelet Disorders; Blood Coagulation and Hemostatic Disorders; Transfusion Medicine; Infections in Hematology; Hematopoietic Stem Cell Transplantation; CAR-T and Other Cell-based Immune Therapies; and Gene Therapy.
UR - http://www.scopus.com/inward/record.url?scp=85118165808&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/HS9.0000000000000643
DO - https://doi.org/10.1097/HS9.0000000000000643
M3 - Review article
C2 - 34522845
SN - 2572-9241
JO - HemaSphere
JF - HemaSphere
M1 - e643
ER -